13 Analysts Have This To Say About Vertex Pharmaceuticals

Ratings for Vertex Pharmaceuticals VRTX were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $455.69, a high estimate of $550.00, and a low estimate of $371.00. Surpassing the previous average price target of $444.82, the current average has increased by 2.44%.

Investigating Analyst Ratings: An Elaborate Study

The standing of Vertex Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Vertex Pharmaceuticals analyst ratings.

Delving into Vertex Pharmaceuticals's Background

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals: Delving into Financials

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 13.3%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Vertex Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 40.87%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.09% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.71%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.